Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Am J Transplant. 2018 Dec 15;19(6):1671–1683. doi: 10.1111/ajt.15175

Figure 4.

Figure 4.

BFXM the First Year Post Transplant in Eculizumab-Treated Patients. The scatterplot shows the BFXM for all tested patients at the time points indicated. BFXM was expressed as mean channel shift (≥106 was considered positive). Matched-pairs analysis was performed to compare BFXM at baseline to that at 1 year. BFXM indicates B-cell flow cytometric crossmatch; IQR, interquartile range.